Your contact persons

Stephanie Lemke

Senior Investor Relations Manager

Jens Remmers

Head of Treasury & Investor Relations

ESG Ratings & Downloads

ESG Ratings

Several ESG rating agencies provide an independent assessment of our ESG profile. Since 2020, the ESG rating agency Sustainalytics has been evaluating CHEPLAPHARM's ESG information and since 2022, we have received an ESG rating from S&P.
Sustainalytics uses a rating system on a scale of 0 to 50, where a lower value means a better ESG risk rating. In Sustainalytics' current ESG rating, CHEPLAPHARM receives a score of 26.0 ("medium risk"), an improvement of 2.6 points year-on-year. This result places CHE-PLAPHARM among the top 24% of companies in the "Pharmaceuticals" sector.
In the "Corporate Sustainability Assessment" of the rating agency S&P, CHEPLAPHARM is currently rated with 23 points - an improvement of 4 points compared to the previous year. This means that we are currently among the top 26% of companies in the "Pharmaceuticals" sector.

Get to know more about ESG at Cheplapharm.

More information on ESG topics and how Cheplapharm deals with them can be found in the following documents for download:

Increasing transparency

Our ESG Reports


Our codes and policies

Investor Relations entdecken

Weitere ESG-Themenbereiche

Back to top expand_less